35 million women have a sexually transmitted infection (STI) on any given day (2018 data).*1
Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV) are the most prevalent non-viral causes of sexually transmitted infections and accounted for ~$1.1 billion in direct medical costs in 2018.1,2
Cost to the U.S. healthcare system - 2018
(Millions)1
The BD CTGCTV2 FDA-cleared assay is designed to detect CT, GC, and TV—the 3 most prevalent non-viral sexually transmitted infections—in a single test.1,6,7
*2018 data.
CT, Chlamydia trachomatis; FDA, Food and Drug Administration; GC, Neisseria gonorrhoeae; STI, sexually transmitted infection; TV, Trichomonas vaginalis.
1. Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States, CDC. 2021. Accessed 29 Apr 2022.
2. Kreisel KM et al. Sex Transm Dis. 2021;48(4):208–14.
3. Chlamydia – CDC Fact Sheet, CDC. 2022. Accessed 10 Apr 2022.
4. Gonorrhea – CDC Fact Sheet, CDC. 2022. Accessed 10 Apr 2022.
5. Trichomoniasis – CDC Fact Sheet, CDC. 2022. Accessed 10 Apr 2022.
6. Van Der Pol B et al. Sex Transm Dis. 2021;48(2):134–40.
7. BD CTGCTV2 for BD MAX™ System Package Insert [P0237].
Learn more about our BD Women’s Health solutions
This form is only intended for use by healthcare professionals seeking additional information about BD products and solutions. Patients seeking health and treatment information should contact their healthcare professional and can find additional resources from ACOG and the American Cancer Society.
Do not submit protected health information (PHI) or patient information (PII) through this form. If you do submit PHI or PII, your question may not be answered, as the information will be deleted to protect your privacy.